Drug
Coltuximab ravtansine clinical trials
Also written SAR3419.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
5 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2011 | 2 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses coltuximab ravtansine is read from its arms, and is right about nine times in ten.
Testing it · 5
- SAR3419 in Acute Lymphoblastic LeukemiaTerminatedPhase 2SanofiNCT01440179Written as SAR3419
- SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) PatientsCompletedPhase 2SanofiNCT01472887Written as SAR3419
- Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedPhase 2SanofiNCT01470456Written as SAR3419
- SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's LymphomaCompletedPhase 1SanofiNCT00796731Written as SAR3419
- Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's LymphomaCompletedPhase 1SanofiNCT00549185Written as SAR3419
Codes
What other systems call coltuximab ravtansine · ClinicalTrials.gg INT005978
- MeSH (NLM) C569646coltuximab ravtansineOne source NLM
- UNII (FDA) MRS84YT9L2COLTUXIMAB RAVTANSINEConfirmed FDA, NLM
- NCI Thesaurus C71009Coltuximab RavtansineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C569646 | coltuximab ravtansine | One source NLM |
| UNII (FDA) | MRS84YT9L2 | COLTUXIMAB RAVTANSINE | Confirmed FDA, NLM |
| NCI Thesaurus | C71009 | Coltuximab Ravtansine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.